TrialBreast cancer (Tokyo, Japan)2024

Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Toshinari Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.